Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 11/20 | 0.54 |
| ▸ | PTPRC | P08575 | 4/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26577327 | 0.90 | PDK2 (0.55) | PDK2GAAKMT2AHSD17B10 | |
| SCHEMBL26573428 | 0.87 | PDK2 (0.52) | PDK2PTPRCCTSLPTPN13GAA | |
| SCHEMBL30571717 | 0.83 | PTPRC (0.59) | PDK2PTPRCCTSLPTPN13 | |
| SCHEMBL26116640 | 0.83 | PTPRC (0.59) | PDK2PTPRCCTSLPTPN13 | |
| SCHEMBL26581011 | 0.82 | PDK2 (0.54) | PDK2PTPRCCTSLPTPN13 | |
| SCHEMBL26560867 | 0.80 | PDK2 (0.58) | PDK2PTPRCCTSLPTPN13GAA | |
| SCHEMBL25366472 | 0.75 | PDK2 (0.69) | PDK2PTPRCGAAKMT2A | |
| SCHEMBL30530873 | 0.75 | PDK2 (0.69) | PDK2PTPRCGAAKMT2A | |
| SCHEMBL30572166 | 0.75 | PTPRC (0.59) | PDK2PTPRCCTSLPTPN13 | |
| SCHEMBL26115268 | 0.75 | PTPRC (0.59) | PDK2PTPRCCTSLPTPN13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023183405-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |